Month: November 2017

Capgemini named the “Growth Partner of the Year” by Backbase, the fastest-growing FinTech software company

Capgemini named Backbase Growth Partner of the Year PARIS, 30-Nov-2017 — /EuropaWire/ — Capgemini today announced that it has been named the “Growth Partner of the Year” by Backbase, the fastest-growing FinTech software company. Presented at the annual Backbase Connect conference, the award recognizes Capgemini as the alliance partner with the largest number of Backbase implementations in 2017. With

Nemetschek Group at the BIM World in Munich: Building the Future Together

MUNICH, 30-Nov-2017 — /EuropaWire/ — The Nemetschek Group, a leading global software provider in the AEC industry (Architecture, Engineering, Construction), is presenting 11 of its brands at the BIM World, which opens its doors today in Munich. Under the slogan “Building the Future Together”, Allplan, Bluebeam, Crem Solutions, Data Design System, dRofus, Graphisoft, Nevaris, SCIA, SDS/2,

Sky Jeremy Darroch on the digital Wild West: time for tech giants to experience the formal scrutiny or regulation of media companies

Opinion piece from Jeremy Darroch Group Chief Executive, Sky Originally published in The Times on Tuesday 28 November 2017 Isleworth, United Kingdom, 30-Nov-2017 — /EuropaWire/ — Every day new headlines are written about inappropriate video appearing on YouTube, about fake news or Russian funded political ads on Facebook or the vile abuse poured out on Twitter. European policy

Fraunhofer-Alumni-Summit 2017 in Stuttgart: Programmierbare Materialien forschungsprojekte

© Foto Fraunhofer IAO, Ludmilla ParsyakDie fünf Science-Slamer gemeinsam mit Dr. Hanna Proner, Leiterin Personal- und Forschungsmarketing Zeitverlag Gerd Bucerius GmbH & Co. KG und Prof. Kurz, Vorstand für Personal, Recht und Verwertung der Fraunhofer- Gesellschaft und Vorstandsvorsitzender des Fraunhofer-Alumni e. V. Auf dem Bild zu sehen: Dr. Hanna Proner, Björn Senf, Dr. Karl-Sebastian Mandel,

GSK: NDA submission to US FDA for single-dose tafenoquine for the radical cure of Plasmodium vivax malaria

Regulatory milestone affirms GSK’s strong commitment and scientific capabilities to fighting infectious diseases  LONDON/GENEVA, 29-Nov-2017 — /EuropaWire/ — GSK and Medicines for Malaria Venture (MMV) today announced the submission of a new drug application (NDA) by GSK to the United States Food and Drug Administration (FDA), seeking approval of single-dose tafenoquine for the radical cure (prevention

GSK on UK Government’s Industrial Strategy: Meaningful targets, sustained efforts and coherent implementation will be critical to this strategy’s success

LONDON, 29-Nov-2017 — /EuropaWire/ — Responding to the launch of the Industrial Strategy White Paper, published today by the UK Government, Phil Thomson, President, Global Affairs, at GSK said: “A new, long-term industrial strategy for the country is important and welcome. We need to take an integrated approach across government, the public and private sectors, to develop

ViiV Healthcare begins phase III study on long-acting two-drug regimen in virally suppressed adults with HIV-1 infection

The ATLAS-2M study will evaluate injections every two months in virally suppressed patients LONDON, 29-Nov-2017 — /EuropaWire/ — Today (27 November 2017) ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the start of a phase III study with a two-drug regimen of long-acting, injectable